NL-OMON21617已完成不适用
Reversal of oral direct factor Xa inhibitors rivaroxaban and apixaban, by two different dosages of prothrombin complex concentrate (Cofact®).
S. MiddeldorpAcademic Medical CenterMeibergdreef 9Amsterdams.middeldorp@amc.uva.nl0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects.
Elise S. Eerenberg, MD; Pieter W. Kamphuisen, MD; Meertien K. Sijpkens, BSc; Joost C. Meijers, PhD; Harry R. Buller, MD; Marcel Levi, MD
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy male subjects as documented by laboratory screen tests (including HIV/HBV/HCV screening), personal medical history and normal physical examination;
- •2. Age ≥18 years, < 50 years;
排除标准
- •1. History of allergic reaction to blood products;
- •2. Current participation in any other investigational drug study or within the past 30 days;
研究者
相似试验
招募中
不适用
Predicting Outcomes in ICH Patients on Direct Factor Xa InhibitorsIntra Cerebral HemorrhageNCT06383741Insel Gruppe AG, University Hospital Bern200
已完成
不适用
Reversal of oral direct factor Xa inhibitors rivaroxaban and apixaban by two different dosages of prothrombin complex concentrate (Cofact®)use of anticoagulation10047075NL-OMON37035Academisch Medisch Centrum12
已完成
4 期
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery DiseasePeripheral Arterial DiseaseNCT05009862Vanderbilt University Medical Center60
已完成
4 期
APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AFAtrial FibrillationAcute Coronary SyndromeCoronary Artery DiseaseNCT02789917LMU Klinikum403
已完成
不适用
Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo StudyDifferences in Laboratory Coagulation ParametersNCT00986635Johann Wolfgang Goethe University Hospital100